A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

Abstract Background Lung cancer is most common among older individuals. However, polypharmacy and comorbidities, which are also more common in older individuals, can limit treatment options. Previous studies suggest that afatinib can be used safely and effectively in elderly patients. This study inv...

Full description

Bibliographic Details
Main Authors: Yuji Minegishi, Ou Yamaguchi, Shunichi Sugawara, Shoichi Kuyama, Satoshi Watanabe, Kazuhiro Usui, Masahide Mori, Osamu Hataji, Toshihiro Nukiwa, Satoshi Morita, Kunihiko Kobayashi, Akihiko Gemma
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Elderly patients
Japan
Afatinib
EGFR mutation
Efficacy
Online Access:https://doi.org/10.1186/s12885-021-07861-1

Internet

https://doi.org/10.1186/s12885-021-07861-1

Similar Items